Dornase Alfa Improves the Health-Related Quality of Life Among Brazilian Patients With Cystic Fibrosis-A One-Year Prospective Study

Dornase Alfa Improves the Health-Related Quality of Life Among Brazilian Patients With Cystic Fibrosis-A One-Year Prospective Study

Author Rozov, Tatiana Autor UNIFESP Google Scholar
Oliveira, Viviane Ziebell de Google Scholar
Santana, Maria Angelica Google Scholar
Adde, Fabiola Villac Google Scholar
Mendes, Rita Heloisa Google Scholar
Paschoal, Ilma Aparecida Google Scholar
Caldeira Reis, Francisco J. Google Scholar
Shinzato Higa, Laurinda Yoko Google Scholar
Castro Toledo, Antonio Carlos de Google Scholar
Pahl, Marcia Google Scholar
Pulmozyme Study Grp Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Pará (UFPA)
Universidade de São Paulo (USP)
Universidade Estadual de Campinas (UNICAMP)
Fiocruz MS
Roche Brasil
Abstract Background: Health-related quality of life (HRQOL) measurements provide valuable information about the psychological and social impact of treatment on patients with cystic fibrosis (CF). This study evaluated the HRQOL of Brazilian patients with CF and assessed the changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme) introduction.Patients and Methods: One hundred fifty-six stable patients with CF and 89 caregivers answered the Portuguese-validated version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline (T(0)), and at 3 (T(1)), 6 (T(2)), 9 (T(3)), and 12 (T(4)) months of follow-up. Eighteen patients were excluded because they did not fulfill the inclusion criteria. the patients were analyzed in two groups: those aged 6-11 years and those aged 14 years and older. ANOVA for observed repeated results and the last observation carried forward (LOCF) method for missing data were used for the statistical analysis.Results: After 1 year of follow-up, there was significant improvement in respiratory symptoms (T(4) - T(0) = 8.1; 95% confidence interval (95% CI) = [2.1;14.0]; effect size (ES) = 0.35; P<0.001), Emotional Functioning (T(4) - T(0) = 5.6; 95% CI = [1.1;10.1]; ES = 0.31; P<0.05), Social Functioning (T(4) - T(0) = 6.0; 95% CI = [1.3;11.7]; ES = 0.31; P<0.05), Body Image (T(4) - T(0) = 11.9; 95% CI = [4.1;19.7]; ES = 0.42; P<0.05), and Treatment Burden (T(4) - T(0) = 5.3; 95% CI = [0.3;10.3]; ES = 0.24; P<0.05) domains in the younger group. A significant improvement in Role Functioning (T(4) - T(0) = 6.1; 95% CI = [1.1;11.1]; ES = 0.40; P<0.05), Body Image (T(4) - T(0) = 12.6; 95% CI = [3.5;21.7]; ES = 0.46; P<0.05), and Weight (T(4) - T(0) = 11.7; 95% CI = [1.8;21.6]; ES = 0.40; P<0.05) was obtained in the older group. the caregivers' CFQ-R showed improvements in the Digestive Symptoms (T(4) - T(0) = 5.5; 95% CI = [1.5;9.4]; ES = 0.30; P<0.05), Respiratory Symptoms (T(4) - T(0) = 7.6; 95% CI = [3.9;11.4]; ES = 0.48; P< 0.05), and Weight (T(4) - T(0) = 10.1; 95% CI = [1.6;18.6]; ES = 0.26; P<0.05) domains.Conclusion: the introduction of dornase alfa improved the HRQL of the patients with CF during the first year of treatment. Pediatr Pulmonol. 2010; 45:874-882. (C) 2010 Wiley-Liss, Inc.
Keywords cystic fibrosis
quality of life
Language English
Sponsor Roche, Brazil
Date 2010-09-01
Published in Pediatric Pulmonology. Hoboken: Wiley-liss, v. 45, n. 9, p. 874-882, 2010.
ISSN 8755-6863 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 874-882
Access rights Closed access
Type Article
Web of Science ID WOS:000281628700005

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account